MedTrace Logo

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

NCT02371187 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-04-10

Study results available
· View outcomes & findings →

Summary

Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.

Conditions

  • Physical Activity

Interventions

DRUG

Dapagliflozin

Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.

DRUG

Placebo

Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Christopher Bell

    lead OTHER

Principal Investigators

  • Christopher Bell, PhD · Colorado State University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02371187 on ClinicalTrials.gov